# Bristol-Myers Squibb (Sweden)

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/bristol-myers-squibb-sweden/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 38.7 |
| Citations | 278,596 |
| City | Solna |
| Country | SE |
| Description | Bristol-Myers Squibb (Sweden) is a research organisation in Solna, SE. OpenAlex records 2,493 works and 278,596 citations for it. 906 researchers list it as their most recent affiliation. |
| Homepage | https://www.bms.com/se |
| OpenAlex ID | https://openalex.org/I4210134011 |
| Researchers | 906 |
| ROR ID | https://ror.org/035hx4w46 |
| Type | company |
| Works | 2,493 |

## University papers

Showing 12 of 14.

- [Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck](https://scholariq.org/papers/nivolumab-for-recurrent-squamous-cell-carcinoma-of-the-head-and-neck/)
- [Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden](https://scholariq.org/papers/nivolumab-plus-ipilimumab-in-lung-cancer-with-a-high-tumor-mutational-burden/)
- [Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/nivolumab-plus-ipilimumab-in-advanced-non-small-cell-lung-cancer/)
- [First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer](https://scholariq.org/papers/first-line-nivolumab-in-stage-iv-or-recurrent-non-small-cell-lung-cancer/)
- [Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma](https://scholariq.org/papers/idecabtagene-vicleucel-in-relapsed-and-refractory-multiple-myeloma/)
- [Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma](https://scholariq.org/papers/anti-bcma-car-t-cell-therapy-bb2121-in-relapsed-or-refractory-multiple-myeloma/)
- [<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i>-Mutant Lung Adenocarcinoma](https://scholariq.org/papers/i-stk11-lkb1-i-mutations-and-pd-1-inhibitor-resistance-in-i-kras-i-mutant-lung/)
- [Low-Dose Methotrexate for the Prevention of Atherosclerotic Events](https://scholariq.org/papers/low-dose-methotrexate-for-the-prevention-of-atherosclerotic-events/)
- [Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer](https://scholariq.org/papers/genomic-features-of-response-to-combination-immunotherapy-in-patients-with/)
- [Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study](https://scholariq.org/papers/nivolumab-plus-ipilimumab-as-first-line-treatment-for-advanced-non-small-cell/)
- [Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study](https://scholariq.org/papers/five-year-follow-up-of-nivolumab-in-previously-treated-advanced-non-small-cell/)
- [Inflammatory Biomarkers, Hormone Replacement Therapy, and Incident Coronary Heart Disease](https://scholariq.org/papers/inflammatory-biomarkers-hormone-replacement-therapy-and-incident-coronary-heart/)

## University top topics

Showing 8 of 25.

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
- [Pharmacogenetics and Drug Metabolism](https://scholariq.org/topics/pharmacogenetics-and-drug-metabolism/)
- [Receptor Mechanisms and Signaling](https://scholariq.org/topics/receptor-mechanisms-and-signaling/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Drug Transport and Resistance Mechanisms](https://scholariq.org/topics/drug-transport-and-resistance-mechanisms/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.